「英中对照」Varda Space Industries完成2.51亿美元D轮融资 用于扩大太空药物加工业务

California-based Varda Space Industries has hit a total of $598m to support its space-based manufacturing ambitions.总部位于加利福尼亚州的 Varda Space Industries 已累计获得 5.98 亿美元，以支持其天基制造雄心。

Most recently, $251m was raised from investors in a Series D financing round, a later-stage investment used by companies to fund further growth and expansion, as it works to scale its pharmaceutical processing operations in space.最近，该公司在 D 轮融资中从投资者处筹集了 2.51 亿美元；D 轮融资是企业用于推动进一步增长与扩张的后期投资，目前该公司正致力于扩大其太空药物加工业务。

The latest investment brings Varda's total capital raised to $598m. 最新投资使 Varda 的总融资额达到 5.98 亿美元。 

Varda develops orbital processing platforms designed to manufacture materials in microgravity before returning them to Earth.Varda 开发轨道加工平台，用于在微重力环境下制造材料，随后将其送回地球。

The company is applying the technology to pharmaceutical manufacturing, investigating whether processing in microgravity can produce active pharmaceutical ingredients (APIs) and drug formulations with properties that are difficult to achieve under terrestrial conditions.该公司正将这项技术应用于药物制造，研究在微重力环境下加工能否生产出具有地面条件下难以实现的特性的活性药物成分（APIs）和药物制剂。

Processing pharmaceuticals in microgravity在微重力环境下加工药物

Varda's W-Series spacecraft are its orbital manufacturing vehicles, combining a processing module with a re-entry capsule. Varda 的 W 系列航天器是其轨道制造飞行器，将加工模块与返回舱结合在一起。 

They carry materials into low Earth orbit, where they can be processed in microgravity before being returned to Earth.它们将材料送入近地轨道，在那里于微重力环境下进行加工，然后被送回地球。

The company said the absence of gravity can enable APIs to crystallise in ways that are not possible under terrestrial conditions, creating opportunities for new drug formulations.该公司表示，失重环境能够使 APIs 以地面条件下不可能实现的方式结晶，从而为新型药物制剂创造机会。

Pharmaceutical crystallisation is one of the main applications being investigated by Varda, with the company working with pharmaceutical partners to assess whether its orbital processing platform can produce materials with different properties from those manufactured on Earth.药物结晶是 Varda 正在研究的主要应用之一，该公司正与制药合作伙伴合作，评估其轨道处理平台能否生产出与地球制造材料具有不同特性的材料。

The company said it has completed six successful re-entry missions since its first mission launched in 2023, with more than a dozen additional launches and re-entries planned through 2028.该公司表示，自2023年首次任务发射以来，其已完成六次成功的再入任务，并计划到2028年再进行十余次发射和再入。

Scaling orbital manufacturing扩大轨道制造规模

The latest funding will be used to increase the frequency of Varda's missions, expand its pharmaceutical partnerships and develop its manufacturing infrastructure.最新资金将用于提高 Varda 的任务频率、扩大其制药合作伙伴关系并发展其制造基础设施。

On 1 October, Varda announced that two of its W-Series spacecraft had launched on the same rocket for the first time. 10月1日，Varda 宣布其两艘 W 系列航天器首次由同一枚火箭发射。 

The W-8 and W-9 vehicles were launched aboard SpaceX's Transporter-18 rideshare mission from Vandenberg Space Force Base.W-8 和 W-9 飞行器搭载 SpaceX 的 Transporter-18 拼车任务，从范登堡太空军基地发射。

The company said operating multiple spacecraft will support a higher mission cadence as it scales its in-space manufacturing operations.该公司表示，在扩大太空制造业务规模之际，运行多艘航天器将支持更高的任务节奏。

Varda's longer-term goal is to produce pharmaceuticals in space for use by patients on Earth.Varda 的长期目标是在太空生产药物，供地球上的患者使用。

The latest investment follows $187m in Series C funding raised in 2025 and $90m in Series B funding raised in 2024, which Varda used to develop its in-space manufacturing and re-entry capabilities.在此笔最新投资之前，Varda 于2025年募集了 $187m 的 C 轮融资，并于2024年募集了 $90m 的 B 轮融资，这些资金被用于发展其太空制造和再入能力。